Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/266860
COMPARTIR / EXPORTAR:
SHARE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | PYODIAGPA, Pyocyanin as a new biomarker for diagnosis of Pseudomonas aeruginosa infections |
Autor: | Rodríguez, Bárbara; Pascual, Nuria; Pastells, Carme; Martín-Gómez, María Teresa; Vilaplana, Lluïsa; Marco, María Pilar CSIC ORCID CVN | Fecha de publicación: | 16-nov-2021 | Resumen: | P. aeruginosa infections, like those caused by many other hospital bacteria, are becoming more difficult to treat because of the increasing development of antibiotic resistance processes and the fewer new antibiotics that are being developed. Currently the gold standard technology for diagnosis of infections is based on sample plate cultures, which have several limitations regarding sensitivity, especially in the case of previous antimicrobial therapy. In this context, we have developed a highly sensitive, specific and reliable immunochemical assay to detect pyocyanin (PYO), the most important virulence factor of P. aeruginosa. The assay uses a high affinity monoclonal antibody raised against the precursor 1-hydroxyphenazine (1-OHphz) hapten derivatives. PYO is a redox-active phenazine responsible of the characteristic blue-green color of these bacteria that has been demonstrated to induce neutrophil apoptosis, interleukin release and weakness of the immune system. The microplate-based ELISA developed is able to achieve a LoD of 0.07 nM which is much below the concentrations reported to be found in clinical samples (130 ¿M in sputa and 2.8 ¿M in ear secretions To our knowledge does not exist in the market any rapid and specific diagnostic kit to detect this biomarker. Thus, the validation of this assay from a clinical perspective would render a faster, reliable diagnostic tool, opening the possibility to apply more appropriate specific treatment, reducing adverse effects and the development of antimicrobial resistance mechanisms. With this aim, the tasks included in this valorization project have included the assessment of PYO as biomarker of P. aeruginosa respiratory infections and the validation of the immunoassay for its detection. Moreover, the market and the need for an in vitro diagnostic (IVD) method have be evaluated, studying the possible commercialization of this assay implemented as a point of care device. | URI: | http://hdl.handle.net/10261/266860 |
Aparece en las colecciones: | (IQAC) Comunicaciones congresos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Abstract PYODIAGPA-Luisavilaplana Jornadas 2021.docx | 13,84 kB | Microsoft Word XML | Visualizar/Abrir |
CORE Recommender
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.